Economic evaluation of rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs for the treatment of osteoarthritis☆
References (64)
- et al.
Economics of osteoarthritis: A global perspective
Bailliere's Clin Rheumatol
(1997) Recent considerations in nonsteroidal anti-inflammatory drug gastropathy
Am J Med
(1998)- et al.
A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis
Gastroenterology
(1999) Approaches to nonsteroidal antiinflammatory drug use in the high-risk patient
Gastroenterology
(2001)- et al.
Management of NSAID-induced gastropathy: An economic decision analysis
Clin Ther
(1997) Direct medical costs of disease and gastrointestinal side effects during treatment for arthritis
Am J Med
(1988)- et al.
Agents used in the prevention and treatment of nonsteroidal anti-inflammatory drug-associated symptoms and ulcers
Am J Med
(1998) - et al.
Coprescribing of nonsteroidal anti-inflammatory drugs and cytoprotective and antiulcer drugs in Nova Scotia's senior population
Clin Ther
(1995) Progress in prophylaxis against nonsteroidal anti-inflammatory drug-associated ulcers and erosions
Am J Med
(1998)- et al.
Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: A randomized, double-blind, placebo-controlled trial
Arthritis Rheum
(2000)
Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: An overview of epidemiologic studies published in the 1990s
Arch Intern Med
Variability in risk of gastrointestinal complications with individual nonsteroidal anti-inflammatory drugs: Results of a collaborative meta-analysis
Br Med J
Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States
Arthritis Rheum
Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee. American College of Rheumatology
Arthritis Rheum
Guidelines for the medical management of osteoarthritis. Part I. Osteoarthritis of the hip. American College of Rheumatology
Arthritis Rheum
Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase
Proc Natl Acad Sci U S A
Nonsteroidal anti-inflammatory drugs and gastrointestinal disease
Rofecoxib
Drugs
Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs
JAMA
Treatment with rofecoxib required less gastrointestinal (GI) co-medication and fewer GI procedures than nonspecific cyclooxygenase inhibitors (NSAIDs)
Arthritis Rheum
Overview of the Arthritis Cost Consequence Evaluation System (ACCES): A pharmacoeconomic model for celecoxib
Pharmacoeconomics
Health economic comparison of rofecoxib versus conventional nonsteroidal antiinflammatory drugs for osteoarthritis in the United Kingdom
J Med Econ
A framework for evaluating the clinical consequences of initial therapy with NSAIDs, NSAIDs plus gastroprotective agents, or celecoxib in the treatment of arthritis
Pharmacoeconomics
An economic model for determining the costs and consequences of using various treatment alternatives for the management of arthritis in Canada
Pharmacoeconomics
Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor in Switzerland
Pharmacoeconomics
A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis
Arch Intern Med
Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium
Arthritis Rheum
The cost-effectiveness of misoprostol in preventing serious gastrointestinal events associated with the use of nonsteroidal antiinflammatory drugs
Arthritis Rheum
The cost-effectiveness of misoprostol for nonsteroidal antiinflammatory drug-associated adverse gastrointestinal events
Arthritis Rheum
Choice of NSAID and management strategy in rheumatoid arthritis and osteoarthritis. The impact on costs and outcomes in the UK
Pharmacoeconomics
The economic consequences of NSAID-induced gastropathy: The French context
Scand J Rheumatol Suppl
Cited by (42)
El uso de coxibs, en la artritis y artrosis, sólo es coste-efectivo en pacientes con antecedentes de hemorragia digestiva
2014, Revista Medica Clinica Las CondesImpact of a general practitioner educational intervention on osteoarthritis treatment in an elderly population
2005, American Journal of MedicineComparison of conventional NSAIDs and cyclooxygenase-2 inhibitors in outpatients
2005, Revue du Rhumatisme (Edition Francaise)Comparison of conventional NSAIDs and cyclooxygenase-2 inhibitors in outpatients
2005, Joint Bone SpineCitation Excerpt :This study investigated the use of NSAIDs, one of the most widely prescribed medication classes in the world. Side effects of NSAIDs cause a huge economic burden related to both the cost of treatment and 2 days of work lost [25,26]. Our study suggests that the universal health insurance database in France is a good epidemiological tool for studying prescriptions of medications, medication combinations, and patient profiles.
Rofecoxib versus non-steroidal anti-inflammatory drugs in arthrosis treatment: Cost-effectiveness analysis for Spain
2004, Revista Clinica EspanolaUtilization of nonsteroidal anti-inflammatory drugs and antisecretory agents: A managed care claims analysis
2004, American Journal of MedicineCitation Excerpt :Importantly, while gastroprotection was prescribed in only 2% to 5% of incident NSAID users, use of gastroprotective agents was nearly 61% lower in users of COX-2 inhibitor than in users of traditional NSAIDs. This issue is of particular importance since the cost-effectiveness of COX-2 inhibitors may depend in large part on the rate of coprescription of gastroprotective agents (17,29,30). However, it is difficult to compare this study with ours because the former included only patients older than 65 years and Canadian patients are subjected to more restrictive formulary management.
- ☆
Portions of this research were presented at the 23rd Annual Meeting of the Society of General Internal Medicine, Boston, Massachusetts, May 4–6, 2000.